Mark Burkard, MD, PhD
The UW Molecular Tumor Board: reading the unique fingerprint of each individual cancer.
The UW Molecular Tumor Board is a state-wide clinical service and research resource. The tumor board is a collaborative effort that virtually and physically brings together investigators in medical oncology, radiation oncology, pathology, molecular pathology and genetics, as well as colleagues at cancer delivery sites around the state including Gundersen, Aurora, Marshfield, ThedaCare, Fox Valley Hematology Oncology, and ProHealth. The tumor board serves as a resource to evaluate the meaning and context of genomic information about a patient’s tumor. After reviewing the clinical case, histopathology, and genomic information, the molecular tumor board develops a recommendation for a precision clinical trial or off-label medication individualized for the patient, in accordance with a pre-established guidance document. Over the next year this collaborative program plans will expand the reach of the tumor board to other sites around Wisconsin including Aspirus, Mercy/Janesville and Columbia St. Mary’s, to build resources for data sharing, and to pilot investigations of unusual cases.